SPDL1 and extranodal nasal NK/T cell lymphoma: Likewise, Kim and team discovered that levels of sPD-L1 were predictors of how patients with extranodal NK/T cell lymphoma would respond to pembrolizumab treatment, showing how useful sPD-L1 is in treatment settings [65].